The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially growing the company’s future revenue ...

The Indian Medical Parliamentarians’ Forum (IMPF), a cross-party collective of 45 medical professionals turned ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

The Indian Medical Parliamentarians Forum has urged urgent government action to prevent life-threatening treatment ...

BioMarin Pharmaceutical’s strong rare disease drug portfolio and Amicus acquisition drive a ‘Buy’ rating. Click here to read my latest analysis of BMRN stock.

A couple struggling to access to a vital cancer treatment say they are are "extremely stressed" by the uncertainty in its supply.

Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses ...

Important Safety Information Indication Elfabrio ® (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed ...

Elfabrio (R) (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed diagnosis of Fabry disease (deficiency of ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

The FDA approves the first gene therapy for a rare immune disorder, a landmark decision for genetic medicine, treatment ...